Advertisement

Topics

Latest Biotechnology, Pharmaceutical and Healthcare News from Pharmafile

00:19 EDT 17th July 2018 | BioPortfolio

Here are the most relevant search results for "Pharmafile" found in our extensive news archives from over 250 global news sources.

More Information about Pharmafile on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Pharmafile for you to read. Along with our medical data and news we also list Pharmafile Clinical Trials, which are updated daily. BioPortfolio also has a large database of Pharmafile Companies for you to search.

Showing News Articles 1–25 of 839 from Pharmafile

Monday 16th July 2018

Senate claims Novartis misled public on Trump lawyer deal

A report released by the United States Senate has found that Novartis’ relationship with Donald Trump’s long-time lawyer Michael Cohen “was longer and more detailed than previously disclosed by the company” and that Novartis “explicitly sought to hire Michael Cohen to provide the company ‘access to key policymakers’ in the Trump administration.” Novartis had claimed that correspond...

FDA expands Pfizer and Astellas' Xtandi into castration-resistant prostate cancer

Astellas and Pfizer have revealed that their androgen receptor inhibitor Xtandi (enzalutamide) has received approval from the FDA to expand its label indications to include the treatment of metastatic castration-resistant prostate cancer (CRPC). read more

FDA approves first smallpox therapy to defend against bioterrorism

The FDA has announced that it has awarded marketing authorisation to SIGA Technologies’ TPOXX (tecovirimat) in the first approval of a drug specifically designed to treatment smallpox. But as the disease was wiped out in 1980, the motivation behind the decision is less conventional. Rather than authorise the drug for the traditional reasons, the US regulator confirmed that the therapy had been a...

European cannabis market set to be worth €115.7 billion by 2028

The European cannabis market is set to be worth €115.7 billion by 2028, according to a report released by the market intelligence firm Prohibition Partners. The findings published in the 3rd edition of the European Cannabis Report, suggest that the cannabis market is set to experience significant growth over the coming decade as demand for cannabis increases for both medical and recreational pur...

Indivior shares soar as US judge rules against Dr Reddy

Shares in the London listed addiction specialist Indivior surged in price today, as the Indian pharmaceutical company Dr Reddy’s Laboratories was blocked from selling generic versions of Indivior’s bestselling opioid addiction treatment, Suboxone Film, in the United States. Indivior shares plummeted on Wednesday of last week as the company issued a “profit warning” related to the loss of S...

Friday 13th July 2018

GSK confirms £250m deal to sell experimental drug to Dermavent Sciences

British company GlaxoSmithKline has announced that it will sell the rights to its experimental dermatology drug, tapinarof, to Roivant Sciences’ subsidiary Dermavent Sciences, in a deal worth up to £250 million. Dermavent made an initial payment of £150 million for the rights to tapinarof, with an agreed future milestone payment of an additional £100 million if the drug meets developmental ta...

J&J ordered to pay $4.68 billion to talc-powder plaintiffs

A Missouri jury has ordered the New Jersey-based healthcare company Johnson and Johnson to pay $4.69 billion to 22 women who claimed that the multinational’s talc-based products had caused them to develop ovarian cancer. The jury awarded plaintiffs $550 million in compensatory damages and $4.14 billion in punitive damages in a record pay-out that has been described by a J&J spokesperson as ...

Alvogen court case causes Nevada Judge to halt execution

A Nevada Judge has temporarily prevented the use of the sedative midazolam, in the execution of the twice convicted killer Scott Raymond Dozier, following objections from the New Jersey-based multinational Alvogen that stated it does not want its drug used in “botched” executions. In claiming that the Nevada Department of Corrections had obtained the drug illegally, the pharmaceutical company ...

Thursday 12th July 2018

Takeda's Ninlaro clears Phase 3 endpoint as maintenance therapy in multiple myeloma

After making headlines with its mammoth deal to acquire Shire earlier this year, Takeda has emerged with new Phase 3 data for its oral proteasome inhibitor Ninlaro (ixazomib). The findings showed that the drug met its primary endpoint with a statistically significant improvement in progression-free survival (PFS) versus placebo as a maintenance therapy for multiple myeloma in adult patients who re...

Otsuka snaps up Visterra in $430 million deal

Otsuka Pharmaceutical has announced it has reached a definitive, board-approved agreement with Visterra to acquire the latter company in an all-cash transaction to the value of $430 million. read more

AbbVie and Janssen announce failure of cancer drug Imbruvica in Phase 3 trial

AbbVie and Janssen have announced that Imbruvica (ibrutinib) failed to achieve the primary endpoint in a late-stage study assessing its use in patients with treatment-naïve diffuse large B-cell lymphoma, an aggressive form of non-Hodgkin lymphoma. The Phase 3 DBL3001 study found that Imbruvica did not improve event-free survival in previously untreated diffuse large B-cell lymphoma patients. Howe...

AbbVie and Janssen announce failure of cancer drug in Phase 3 trial

AbbVie and Janssen have announced that Imbruvica (ibrutinib) failed to achieve the primary endpoint in a late-stage study assessing its use in patients with treatment-naïve diffuse large B-cell lymphoma, an aggressive form of non-Hodgkin lymphoma. The Phase 3 DBL3001 study found that Imbruvica did not improve event-free survival in previously untreated diffuse large B-cell lymphoma patients. Howe...

Pfizer restructures in preparation for potential sell off

Pfizer has announced plans to reorganise into three separate units through the separation of its consumer health care business from the other two arms of the company. Pfizer is currently comprised of two segments: Innovative Health and Essential Health. The restructuring will involve the formation of a third segment which will take responsibility for all of Pfizer’s over-the-counter brands which...

Pfizer restructures in preperation for potential sell off

Pfizer has announced plans to reorganise into three separate units through the separation of its consumer health care business from the other two arms of the company. Pfizer is currently comprised of two segments: Innovative Health and Essential Health. The restructuring will involve the formation of a third segment which will take responsibility for all of Pfizer’s over-the-counter brands which...

Novartis pulls out of antibiotics, cuts 140 staff

Novartis has announced that it is to terminate its research operations into antibiotics and antivirals in a reorganisation effort that will see 140 staff cut from the company. read more

Wednesday 11th July 2018

NICE approves treatment for rare and deadly childhood cancer

NICE has recommended that monoclonal antibody dinutuximab beta be used in treating high-risk neuroblastoma – a rare and deadly form of cancer that mainly affects young children. The cancer drug will be given to patients aged 12 months or older whose disease has at least partially responded to first stage chemotherapy, followed by myeloablative therapy and stem cell transplant, but only if they h...

Celgene and Acceleron's blood disorder drug smashes endpoints at Phase 3

Celgene and Acceleron have lifted the curtain on new Phase 3 data for their erythroid maturation agent (EMA) luspatercept, confirming that it demonstrated a “highly statistically significant improvement” in erythroid response in combination with best supportive care in the treatment of transfusion-dependent beta-thalassemia, meeting the trial’s primary endpoint. read more

UK Government announces £10m antimicrobial resistance research competition

The UK Government’s Department of Health and Social Care has announced the launch of a £10 million research competition aimed at combatting antimicrobial resistance (AMR) as part of its five year antimicrobial resistance strategy. read more

UK Government announces £10m antimcrobial resistance research competition

The UK Government’s Department of Health and Social Care has announced the launch of a £10 million research competition aimed at combatting antimicrobial resistance (AMR) as part of its five year antimicrobial resistance strategy. read more

EMA survey identifies gaps in pharma industry's preparedness for Brexit

An EMA survey has identified gaps in the pharmaceutical industry’s preparedness for Brexit, finding that only 58% of market authorisation holders are on track with their regulatory planning in preparation for the UK’s exit from the European Union in March 2019.   The survey, aimed at identifying centrally authorised products (CAPs) that are at risk of shortages following Brexit, iden...

Wellcome Trust announces £250m fund for high risk ideas

The London-based biomedical research charity the Wellcome Trust, Britain’s wealthiest foundation, has announced the launch of a new £250 million fund that will place “big bets” on ambitious research programmes aimed at fundamentally transforming science and health. Image caption:  Image Credit: Howard Luke read more

Trump forces Pfizer to back down and delay price hikes until 2019

Trump bared his teeth, and it paid off. Following his call-out of Pfizer after the US pharma giant ignored the President’s threats to crack down on drug prices and raised the price of 100 of its drugs, the firm has confirmed it will delay planned price hikes until the beginning of next year. read more

Tuesday 10th July 2018

China opens market to Indian drugs with reduced tariffs

India and China have reached an agreement aimed at reducing tariffs on Indian pharmaceuticals going between the world’s two most populous countries. The agreement to reduce tariffs on Indian medicines is intended to increase imports of Indian drugs into China. The cuts are particularly significant in regards to anti-cancer drugs on which tariffs will be removed entirely in an effort to reduce co...

EMA issues global recall of heart drugs over cancer risk contamination

Several drugs designed for the treatment of high blood pressure and heart conditions have been recalled across Europe over fears they could contain a probable carcinogen and thus pose an increased risk of cancer in users, it has emerged. read more

Sanofi shut down French plant over "astronomical" emission levels

Sanofi announced yesterday that they have stopped production at their plant in the French Pyrenees following complaints that the factory has been “sending astronomical quantities of pollutants into the air." The environmental body French Nature Environnement (FNE), a federation which represents more than 3,000 local associations, filed complaints against the multinational pharmaceutical company ...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks